{"doi":"10.14740/gr1138","title":"Neuroendocrine Markers Insulinoma-Associated Protein 1, Chromogranin, Synaptophysin, and CD56 Show Rare Positivity in Adenocarcinoma Ex-Goblet Cell Carcinoids","abstract":null,"journal":"Gastroenterology Research","year":2019,"id":638867,"datarank":0.26876392038420827,"base_score":1.791759469228055,"endowment":1.791759469228055,"self_citation_contribution":0.26876392038420827,"citation_network_contribution":0.0,"self_endowment_contribution":0.26876392038420827,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1659610,"name":"Ivan Gonzalez","orcid":null,"position":1,"is_corresponding":false},{"id":336441,"name":"Lingxin Zhang","orcid":"0000-0001-5086-2272","position":2,"is_corresponding":false},{"id":476703,"name":"Dengfeng Cao","orcid":"0000-0002-6551-2723","position":3,"is_corresponding":false},{"id":344934,"name":"Chen Yang","orcid":"0000-0002-8257-335X","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Neuroendocrine Markers Insulinoma-Associated Protein 1, Chromogranin, Synaptophysin, and CD56 Show Rare Positivity in Adenocarcinoma Ex-Goblet Cell Carcinoids","abstract":"BACKGROUND: Adenocarcinoma ex-goblet cell carcinoid (AdexGCC) was considered a neuroendocrine adenocarcinoma, despite majority of tumor cells being negative for conventional neuroendocrine markers such as chromogranin and synaptophysin. Recently, insulinoma-associated protein 1 (INSM1) has been identified as a novel neuroendocrine marker that is more sensitive than chromogranin, synaptophysin, and CD56 in pulmonary neuroendocrine tumors. METHODS: We studied this marker in conjunction with chromogranin, synaptophysin, and CD56 in 36 appendiceal AdexGCCs (21 primaries, 15 metastatic). RESULTS: Primary AdexGCCs showed staining for INSM1, chromogranin, synaptophysin, and CD56 in 13/21 (62%), 18/21 (86%), 18/21 (86%), and 9/19 (47%) cases, respectively. However, the mean proportion of tumor cells stained for INSM1, chromogranin, synaptophysin, and CD56 was only 8.0% (median 1%, range 0-70%), 15.7% (median 2%, range 0-70%), 19.9% (median 5%, range 0-90%), and 5.6% (median 0%, range 0-50%), respectively. Metastatic AdexGCCs showed staining for INSM1, chromogranin, synaptophysin, and CD56 in 8/15 (53%), 11/15 (73%), 12/15 (80%), and 3/14 (21%) cases. The mean proportion of tumor cells stained for INSM1, chromogranin, synaptophysin, and CD56 in metastatic tumors was 1% (median 1%, range 0-3%), 12% (median 1%, range 0-85%), 17% (median 5%, range 0-85%), and 2% (median 0%, range 0-20%), respectively. CONCLUSIONS: Primary and metastatic AdexGCCs showed no difference in INSM1, chromogranin, synaptophysin, or CD56 staining. INSM1 exhibits low expression in AdexGCCs and is expressed by a lower proportion of tumor cells compared to chromogranin and synaptophysin.","is_dataset_classified":null,"base_score":1.791759469228055,"endowment":1.791759469228055,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"31236152","pmcid":"PMC6575132","openalex_id":"https://openalex.org/W2989799702","authors":[],"funders":[],"total_grants":0,"fwci":0.4401,"citation_percentile":0.65455519,"influential_citations":0,"citation_trend":[{"year":2020,"count":1},{"year":2022,"count":2},{"year":2024,"count":1},{"year":2025,"count":1}],"oa_status":"gold","license":"cc-by-nc","oa_locations":[{"url":"https://www.gastrores.org/index.php/Gastrores/article/download/1138/1194","host_type":"journal"},{"url":"https://www.gastrores.org/index.php/Gastrores/article/download/1138/1194","host_type":"publisher"},{"url":"http://www.gastrores.org/index.php/Gastrores/article/download/1138/1194\"","host_type":"publisher"},{"url":"https://doi.org/10.14740/gr1138","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/31236152","host_type":"repository"},{"url":"https://digitalcommons.wustl.edu/open_access_pubs/10994","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6575132","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC6575132","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC6575132?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Neuroendocrine Tumor Research Advances","Neuroblastoma Research and Treatments","Lung Cancer Research Studies"],"mesh_terms":[],"keywords":["Chromogranin A","Synaptophysin","Pathology","Medicine","Neuroendocrine differentiation","Neuroendocrine tumors","Immunohistochemistry","Adenocarcinoma","Internal medicine","Gastroenterology","Endocrinology","Cancer","Neuroendocrine","Chromogranin","Insulinoma-associated Protein 1","Adenocarcinoma Ex-goblet Cell Carcinoid"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"doi"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T21:45:22.904739Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}